Literature DB >> 10604745

Nidovirus infections: experimental model systems of human neurologic diseases.

E Lavi1, T Schwartz, Y P Jin, L Fu.   

Abstract

The presence of terminally differentiated slow- and non-dividing cells in the central nervous system (CNS) provides a safe harbor for viral persistence and latency and constitutes a unique immunologic environment for viral infections. Studies of experimental model systems of viral infections of the CNS provide insight into mechanisms of viral persistence and immune-mediated pathology. Nidoviruses are comprised of 2 families of viruses, coronaviruses and arteriviruses, and are common pathogens of humans and a variety of animal species. Both families of viruses contain neurotropic strains that produce experimental neurologic diseases in rodents. These include acute meningitis and encephalitis; acute poliomyelitis; and chronic inflammatory, immune-mediated, demyelination. Coronavirus-induced demyelinating disease mimics many of the pathologic features of Multiple Sclerosis (MS).

Entities:  

Mesh:

Year:  1999        PMID: 10604745      PMCID: PMC7107479          DOI: 10.1097/00005072-199912000-00001

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  10 in total

1.  COVID-19: A Personalized Cardiometabolic Approach for Reducing Complications and Costs. The Role of Aging Beyond Topics.

Authors:  J Saban-Ruiz; D Ly-Pen
Journal:  J Nutr Health Aging       Date:  2020-05-12       Impact factor: 4.075

2.  Demyelination determinants map to the spike glycoprotein gene of coronavirus mouse hepatitis virus.

Authors:  J Das Sarma; L Fu; J C Tsai; S R Weiss; E Lavi
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

3.  Coronavirus neurovirulence correlates with the ability of the virus to induce proinflammatory cytokine signals from astrocytes and microglia.

Authors:  Yun Li; Li Fu; Donna M Gonzales; Ehud Lavi
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

4.  Differential induction of apoptosis in demyelinating and nondemyelinating infection by mouse hepatitis virus.

Authors:  Talya Schwartz; Li Fu; Ehud Lavi
Journal:  J Neurovirol       Date:  2002-10       Impact factor: 2.643

5.  Sequence analysis of the S gene of recombinant MHV-2/A59 coronaviruses reveals three candidate mutations associated with demyelination and hepatitis.

Authors:  J Das Sarma; L Fu; S T Hingley; M M Lai; E Lavi
Journal:  J Neurovirol       Date:  2001-10       Impact factor: 2.643

6.  Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins.

Authors:  Ralph A Tripp; Lia M Haynes; Deborah Moore; Barbara Anderson; Azaibi Tamin; Brian H Harcourt; Les P Jones; Mamadi Yilla; Gregory J Babcock; Thomas Greenough; Donna M Ambrosino; Rene Alvarez; Justin Callaway; Sheana Cavitt; Kurt Kamrud; Harold Alterson; Jonathan Smith; Jennifer L Harcourt; Congrong Miao; Raj Razdan; James A Comer; Pierre E Rollin; Thomas G Ksiazek; Anthony Sanchez; Paul A Rota; William J Bellini; Larry J Anderson
Journal:  J Virol Methods       Date:  2005-09       Impact factor: 2.014

Review 7.  Neuropathogenesis in COVID-19.

Authors:  Marcos Altable; Juan Moisés de la Serna
Journal:  J Neuropathol Exp Neurol       Date:  2020-11-01       Impact factor: 3.685

8.  Coronavirus-induced demyelination occurs in the absence of CD28 costimulatory signals.

Authors:  Donna M Gonzales; Li Fu; Yun Li; Jayasri Das Sarma; Ehud Lavi
Journal:  J Neuroimmunol       Date:  2004-01       Impact factor: 3.478

9.  A combination of mutations in the S1 part of the spike glycoprotein gene of coronavirus MHV-A59 abolishes demyelination.

Authors:  Li Fu; Donna M Gonzales; Jayasri Das Sarma; Ehud Lavi
Journal:  J Neurovirol       Date:  2004-02       Impact factor: 2.643

10.  COVID-19: A Personalized Cardiometabolic Approach for Reducing Complications and Costs. The Role of Aging beyond Topics.

Authors:  J Saban-Ruiz; D Ly-Pen
Journal:  J Nutr Health Aging       Date:  2020       Impact factor: 4.075

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.